Comparing the safety profiles and efficacy rates of newer non-hormonal prescription medications approved by the FDA for treating vasomotor symptoms in menopausal women.
Download run
Fan-out diagram
The searches the AI actually ran for this prompt.
SEED QUERY
Comparing the safety profiles and efficacy rates of newer non-hormonal prescription medications approved by the FDA for treating vasomotor symptoms in menopausal women.
3 real searches · 1 real-search pass
FDA fezolinetant Veozah prescribing information efficacy SKYLIGHT 1 2 liver monitoring boxed warning 2024 labelGoogle ↗
OBSERVED
FDA elinzanetant Lynkuet prescribing information efficacy OASIS 1 2 safety 2025Google ↗
OBSERVED
FDA Brisdelle paroxetine prescribing information vasomotor symptoms efficacy trials safetyGoogle ↗
OBSERVED
Badge and edge weight = share of passes that produced the query. Hover a query for its intent and routing format.
Query classes
Google's semantic query class for every sub-query: what kind of answer each search is after, simulated vs real.
Classifying 3 queries…
Searches and sources
ChatGPT3 real searches · gpt-6
FDA fezolinetant Veozah prescribing information efficacy SKYLIGHT 1 2 liver monitoring boxed warning 2024 label Google ↗
FDA elinzanetant Lynkuet prescribing information efficacy OASIS 1 2 safety 2025 Google ↗
FDA Brisdelle paroxetine prescribing information vasomotor symptoms efficacy trials safety Google ↗
- FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause · fda.gov
- Drug Trials Snapshots: LYNKUET · fda.gov
- label · accessdata.fda.gov
- These highlights do not include all the information needed to use VEOZAH safely and effectively. See full prescribing information for VEOZAH. VEOZAH® (fezolinetant) tablets, for oral useInitial U.S. Approval: 2023 · dailymed.nlm.nih.gov
- These highlights do not include all the information needed to use LYNKUET safely and effectively. See full prescribing information for LYNKUET. LYNKUET® (elinzanetant) capsules, for oral use Initial U.S. Approval: 2025 · dailymed.nlm.nih.gov
- Review · accessdata.fda.gov
Queries
3 queries · click a column to sort
| Query / type | Search | Intent | Query class | Routing format | Cluster | Freq ↓ | Weight |
|---|---|---|---|---|---|---|---|
FDA fezolinetant Veozah prescribing information efficacy SKYLIGHT 1 2 liver monitoring boxed warning 2024 label OBSERVED | Google ↗ AI Mode ↗ | — | — | — | — | 1x of 1 | |
FDA elinzanetant Lynkuet prescribing information efficacy OASIS 1 2 safety 2025 OBSERVED | Google ↗ AI Mode ↗ | — | — | — | — | 1x of 1 | |
FDA Brisdelle paroxetine prescribing information vasomotor symptoms efficacy trials safety OBSERVED | Google ↗ AI Mode ↗ | — | — | — | — | 1x of 1 |